Meet with ASX-listed, Pre-IPO and Startup companies at lunches and networking events - matched to your investment interests and city. Open to retail and professional investors.
How it works
Tell us your city and the sectors you invest in. Takes under a minute.
We match upcoming lunches to your profile and send an invitation by email.
Meet company management over lunch - in person or online, usually at no cost.
Sectors we cover
Critical minerals for the energy shift. Fintech for global trade. Biotech for better health. Whatever matters to you - we'll prioritise the invitations you get.
Upcoming events
We launched just a few weeks ago and are progressively adding events as we grow. Help us grow by forwarding this website link to a friend.
Pitch your story directly to a curated audience of investors, in person or online.
EnquireOur first collaboration with The Armchair Analyst newsletter: Control Bionics. Stock Ticker: CBL Market Cap: ~$31 million Cash Balance: ~$10 million Last Traded Price: $0.058 Control Bionics has an FDA-approved, CE Mark-cleared medical device that reads electrical signals and lets people control devices with their mind. The technology was developed over 20 years ago, with its first “patient” being Stephen Hawking. Think of Elon Musk’s “Neuralink”... but without the brain surgery. Control Bionics tech uses surface EMG. A device placed on the skin reads signals from the brain to the muscles. It has a deal in place with Apple to leverage its BCI (brain-computer interface) firmware. Right now, CBL has distribution agreements with the two largest Assistive Technology distributors in the US, PRC and Tobii. It also recently expanded into the sports and rehabilitation markets. Sports customers include the Kansas City Chiefs, PSG, Hawthorn, GWS, the British Olympic Team, NASCAR teams, and Rugby Australia. It is also one of the Armchair Analyst Foundation “picks”.
In conjunction with Bantry Advisors, we are pleased to invite you to a luncheon with Nova Eye Medical. Stock Ticker: EYE Market Cap: ~$38 million Last Traded Price: $0.13 Nova Eye Medical is a medical technology company that designs, develops, and commercialises advanced devices for the treatment of glaucoma. The technology is anchored by its proprietary iTrack™ canaloplasty portfolio - pioneering microcatheter innovations developed to restore natural eye outflow and preserve delicate anatomy. Think of traditional invasive glaucoma surgeries... but with a precision, surgeon-first handheld injector that leaves tissue largely untouched. Nova Eye's flagship iTrack™ Advance uses an intuitive, engineered delivery system. A compact handheld device that allows surgeons to precisely thread through Schlemm’s canal and clear blockages in real time. It has a global commercial footprint with direct sales infrastructure spanning the United States, Australia, New Zealand, and Europe. Right now, EYE has established distribution pathways serving ophthalmic surgeons across major international markets, alongside its established Molteno3® glaucoma drainage devices for complex cases. It also continues to advance the clinical pipeline for its proprietary 2RT® (Retinal Rejuvenation Therapy) laser technology targeted at intermediate age-related macular degeneration (AMD). Key clinical users and institutional partners include prominent global teaching hospitals, research networks, and specialised ophthalmic surgical centers across the US, Europe, and Asia-Pacific.
Join the mailing list to be notified as soon as new lunches go live.
Join the list
How we host
Invite-only lunches at restaurants and private function rooms in your capital city. Small groups, direct access to company management, real conversation after the presentation.
Bring investors from every city into one room. A Perth-based company can reach east coast investors without booking a multi-city roadshow. At the host's discretion, we'll send an Uber Eats voucher as a thank-you for tuning in.
Selected lunches are recorded and made available to registered investors online, so missing the date doesn't mean missing the opportunity. Availability varies by event - your invitation will note if a replay is offered.
FAQs
Looking to organise a multi-city capital raise or IPO roadshow instead? See Investor Roadshows.
